

**SYT (N-18): sc-8819**

The Power to Question

**BACKGROUND**

The transcriptional coactivator SYT (synovial translocation protein) contains a conserved amino terminal SNH domain and a carboxy-terminal QPGY domain, which is a functioning transcriptional activating sequence. Synovial sarcoma translocation (SSX) proteins, including SSX1-5, are transcriptional repressors that contain a repressor domain in their carboxy-termini. SSX proteins are localized to the nucleus and expressed in testis and several types of cancers and, therefore, they are classified as C/T (cancer/testis) antigens. The t(x;18) translocation results in the fusion of the amino terminus of SYT to the carboxy-terminus of either SSX1 or SSX2; both fusions result in the production of transcriptional activators. SYT-SSX chimeras are detected in most synovial sarcomas. Synovial sarcomas are responsible for up to 10% of soft tissue sarcomas and are histologically characterized as either biphasic or mono-phasic. Genetic analysis indicates that biphasic synovial sarcomas contain SYT-SSX1 fusions, whereas SYT-SSX2 fusions are found in mono-phasic synovial sarcomas, providing additional distinguishing characterization of these subtypes.

**REFERENCES**

- Clark, J., et al. 1994. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. *Nat. Genet.* 7: 502-508.
- Crew, A.J., et al. 1995. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. *EMBO J.* 14: 2333-2340.
- Gure, A.O., et al. 1997. SSX: a multigene family with several members transcribed in normal testis and human cancer. *Int. J. Cancer* 72: 965-971.
- dos Santos, N.R., et al. 1997. Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins. *Hum. Mol. Genet.* 6: 1549-1558.

**CHROMOSOMAL LOCATION**

Genetic locus: SS18 (human) mapping to 18q11.2; Ss18 (mouse) mapping to 18 A1.

**SOURCE**

SYT (N-18) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of SYT of human origin.

**PRODUCT**

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-8819 X, 200 µg/0.1 ml.

Blocking peptide available for competition studies, sc-8819 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

**STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

**APPLICATIONS**


SYT (N-18) is recommended for detection of SYT of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

SYT (N-18) is also recommended for detection of SYT in additional species, including canine, bovine, porcine and avian.


Suitable for use as control antibody for SYT siRNA (h): sc-38449, SYT siRNA (m): sc-38450, SYT shRNA Plasmid (h): sc-38449-SH, SYT shRNA Plasmid (m): sc-38450-SH, SYT shRNA (h) Lentiviral Particles: sc-38449-V and SYT shRNA (m) Lentiviral Particles: sc-38450-V.

SYT (N-18) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Positive Controls: SYT (h): 293T Lysate: sc-178011, IMR-32 cell lysate: sc-2409 or HeLa whole cell lysate: sc-2200.

**DATA**

SYT (N-18): sc-8819. Western blot analysis of SYT expression in non-transfected 293T: sc-117752 (A), human SYT transfected 293T: sc-178011 (B) whole cell lysates and HeLa (C) nuclear extract.



SYT (N-18): sc-8819. Immunoperoxidase staining of formalin fixed, paraffin-embedded human colon tissue showing nuclear and cytoplasmic staining of glandular cells, endothelial cells and interstitial cells.

**SELECT PRODUCT CITATIONS**

- He, R., et al. 2007. Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. *Mod. Pathol.* 20: 522-528.
- Trautmann, M., et al. 2013. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma. *Oncogene* 33: 5006-5016.

**RESEARCH USE**

For research use only, not for use in diagnostic procedures.

**MONOS**  
Satisfaction  
Guaranteed

Try **SYT (D-3): sc-390615** or **SYT (C-3): sc-390266**, our highly recommended monoclonal alternatives to SYT (N-18).